GlassScriptPhysician profile
Tushar Gohel
NPI 1568699304
$3,485.63
in general payments reported to CMS, 2019-2025
24 companies · $560 in 2025
The $560 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $388 · 2021: $306 · 2022: $178 · 2023: $65.69 · 2024: $205 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,837.63 | 2019-2025 | General - Therapies, Overstitch Endoscopic Suturing System, Exalt Model D |
| Abbvie INC. | $489.69 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.88 | 2019-2024 | Trulance, Xifaxan |
| Janssen Scientific Affairs, LLC | $113.70 | 2020 | |
| Janssen Biotech, INC. | $111.34 | 2019-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $85.38 | 2020-2021 | |
| Qol Medical, LLC | $68.26 | 2019-2025 | Sucraid |
| Ambu INC. | $66.85 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.98 | 2020-2024 | Eohilia |
| Madrigal Pharmaceuticals | $60.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $56.47 | 2024-2025 | Voquezna |
| Medtronic, INC. | $54.00 | 2025 | Endoflip |
| Pfizer INC. | $48.76 | 2021-2022 | |
| Lucid Diagnostics INC. | $39.07 | 2021 | |
| Shire North American Group INC | $29.07 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $27.33 | 2025 | |
| Fujifilm Healthcare Americas Corporation | $26.41 | 2022 | |
| Genzyme Corporation | $23.57 | 2025 | |
| Exact Sciences Corporation | $22.95 | 2025 | The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $16.56 | 2025 | |
| Biotronik INC. | $13.95 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tushar Gohel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.